We count our blessings every day! We recognize that we are very fortunate to have the opportunity to do the work we do, to work with the clients we work with and the people that work for those clients, and to collaborate with clinicians who have dedicated their lives to the management of diseases such as TB and HIV. Most importantly, we know how powerful, fun, and rewarding it is to meet and to serve the patients who need and deserve all our help to cure or manage their disease. It is a pleasure and we know it is a privilege to be able to spend our time trying to make a difference in patients’ lives.
We also know that we aren’t, and we don’t try to be, anything more than who we are. We are a small, narrowly focused, group of adherence zealots who happen to have a wealth of subject matter and managerial/executive experience and expertise that allows us to translate the science of adherence into action across disease states and around the world. We pride ourselves on our ability to work in multiple, global, cross-functional teams.
We are committed to making the greatest possible positive impact on patients’ lives and we’re happy to provide information on how we do it.
Where We Work
We are based in Richmond, Virginia and a lot of the work we do is done there. However, that is not where the patients are. That is not where the problems are that we are asked to solve. In our work in global health, the problems and the patients are in the 22 WHO designated high burden regions of the world. In our work with pharmaceutical companies, the problems and the patients are often in developed markets such as North America and Europe. Wherever our patients are, wherever the problems are – that is often where we work.
As a team, we have significant global experience. We’ve worked extensively in China, in Southeast Asia, in India, in South America, and in Africa. We have worked across industries in these regions for more than 25 years.
We serve as both consultant and multiple grantee of the Gates Foundation, focusing on issues relating to medication adherence and differentiated care in Tuberculosis and HIV/AIDS in India, China, and Africa.
The Gates Foundation understood that TB medication adherence is essential for positive treatment outcomes, but little was known about baseline adherence rates, drivers of poor adherence and potential adherence-enhancing interventions, particularly in resource limited settings.
Using structured, insights-oriented interviews with patients, providers, disease state experts, and other key stakeholders, we assembled a practical and actionable set of findings, which served as critical inputs into the adherence elements of the Gates Foundation’s comprehensive strategy to modernize TB delivery.
Directly Observed Therapy (DOT), the established standard of care for TB patient management, is burdensome for patients and negatively impacts retention in care. Alternative adherence monitoring technologies were prohibitively expensive and were inappropriate for TB medication format and supply chains.
We served as global project lead for the development, manufacture, testing, and deployment at scale of a highly accurate, highly affordable, TB blister-compatible medication adherence technology to improve patient medication adherence and to enable and inform differentiated care.
We serve as adherence subject matter experts to Novartis Digital Medicines. In this capacity, we help (i) identify treatments that are unforgiving to poor adherence, (ii) patients or patient demographics that have particular issues with medication adherence, and (iii) match those treatments and those patients with adherence technologies or digital solutions that can address these adherence challenges, enhance patient care, and improve health outcomes.
We serve as advisers to the Virginia Commonwealth University School of Engineering’s Medicines For All Institute, a Bill & Melinda Gates-funded initiative to transform pharmaceutical manufacturing processes to reduce raw material costs and, thereby, improve patient access to life saving global health medications.
Medicines for All
The VCU School of Engineering’s Medicines For All Institute successfully demonstrated its ability to optimize manufacturing processes to reduce the cost of global health medications. M4ALL was seeking additional support from the Gates Foundation to dramatically scale up its capabilities and capacity to further positively impact patient access.
The Arcady Group supported M4ALL in its efforts to dramatically expand its capabilities and capacity. Specifically, we assisted in the development of a detailed business plan and grant proposal for the scale-up of M4ALL. In addition, The Arcady Group helped M4ALL access and engage with global health organizations and generic manufacturers who may be willing sponsors for M4ALL optimization projects.. As a result of these efforts, M4ALL is expected to receive the requested funding and will begin scaling up in the late 2017